Salim Syed
Stock Analyst at Mizuho Securities
(3.41)
# 2,388
Out of 4,966 analysts
1120
Total ratings
45%
Success rate
2.6%
Average return
Main Sectors:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASMB Assembly Biosciences | Reiterated: Buy | $45 → $53 | $29.80 | +77.85% | 41 | Aug 31, 2026 | |
| ATRA Atara Biotherapeutics | Reiterated: Buy | $18 | $9.38 | +91.90% | 82 | Aug 31, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $96 → $110 | $72.44 | +51.85% | 108 | Aug 31, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $170 | $143.72 | +18.29% | 112 | Aug 31, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $25 | $11.39 | +119.49% | 10 | Aug 31, 2026 | |
| AMGN Amgen | Reiterated: Hold | $303 → $352 | $377.35 | -6.72% | 172 | Aug 17, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | $62 → $73 | $54.32 | +34.39% | 18 | Aug 17, 2026 | |
| IOVA Iovance Biotherapeutics | Reiterated: Buy | $10 → $11 | $8.60 | +27.91% | 6 | Aug 17, 2026 | |
| IPSC Century Therapeutics | Reiterated: Buy | $8 | $1.90 | +321.05% | 4 | Aug 17, 2026 | |
| NKTX Nkarta | Reiterated: Buy | $12 | $2.91 | +312.37% | 43 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $47 | $24.59 | +91.13% | 6 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $221 → $241 | $217.15 | +10.98% | 133 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $121 → $137 | $121.47 | +12.79% | 8 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $23 | $4.59 | +401.09% | 81 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 → $118 | $73.77 | +59.96% | 146 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $97 | $24.79 | +291.37% | 4 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $163 | $59.47 | +174.09% | 24 | Jun 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.88 | +431.91% | 6 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $43 | $18.18 | +136.52% | 8 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.31 | +246.32% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $85 | $51.72 | n/a | 23 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $143.93 | n/a | 2 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $24.41 | n/a | 2 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $53 | $27.72 | n/a | 1 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $4.91 | n/a | 1 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.33 | n/a | 73 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $10.54 | n/a | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $65.68 | n/a | 1 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $23.30 | n/a | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.1 | $9.28 | n/a | 1 | Jul 2, 2019 |
Assembly Biosciences
Aug 31, 2026
Reiterated: Buy
Price Target: $45 → $53
Current: $29.80
Upside: +77.85%
Atara Biotherapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $18
Current: $9.38
Upside: +91.90%
BridgeBio Pharma
Aug 31, 2026
Reiterated: Buy
Price Target: $96 → $110
Current: $72.44
Upside: +51.85%
Gilead Sciences
Aug 31, 2026
Reiterated: Buy
Price Target: $170
Current: $143.72
Upside: +18.29%
Kura Oncology
Aug 31, 2026
Reiterated: Buy
Price Target: $25
Current: $11.39
Upside: +119.49%
Amgen
Aug 17, 2026
Reiterated: Hold
Price Target: $303 → $352
Current: $377.35
Upside: -6.72%
Enliven Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $62 → $73
Current: $54.32
Upside: +34.39%
Iovance Biotherapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $10 → $11
Current: $8.60
Upside: +27.91%
Century Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $8
Current: $1.90
Upside: +321.05%
Nkarta
Aug 17, 2026
Reiterated: Buy
Price Target: $12
Current: $2.91
Upside: +312.37%
Aug 5, 2026
Reiterated: Buy
Price Target: $47
Current: $24.59
Upside: +91.13%
Aug 3, 2026
Reiterated: Buy
Price Target: $221 → $241
Current: $217.15
Upside: +10.98%
Aug 3, 2026
Reiterated: Buy
Price Target: $121 → $137
Current: $121.47
Upside: +12.79%
Aug 3, 2026
Reiterated: Buy
Price Target: $27 → $23
Current: $4.59
Upside: +401.09%
Jun 23, 2026
Reiterated: Buy
Price Target: $100 → $118
Current: $73.77
Upside: +59.96%
Jun 23, 2026
Reiterated: Buy
Price Target: $97
Current: $24.79
Upside: +291.37%
Jun 18, 2026
Reiterated: Buy
Price Target: $163
Current: $59.47
Upside: +174.09%
Jun 10, 2026
Reiterated: Buy
Price Target: $10
Current: $1.88
Upside: +431.91%
Mar 30, 2026
Reiterated: Buy
Price Target: $45 → $43
Current: $18.18
Upside: +136.52%
Nov 14, 2025
Reiterated: Buy
Price Target: $8
Current: $2.31
Upside: +246.32%
May 20, 2025
Reiterated: Buy
Price Target: $85
Current: $51.72
Upside: n/a
Nov 22, 2024
Rated: Hold
Price Target: n/a
Current: $143.93
Upside: n/a
Nov 22, 2024
Rated: Hold
Price Target: n/a
Current: $24.41
Upside: n/a
May 28, 2024
Reiterated: Buy
Price Target: $53
Current: $27.72
Upside: n/a
Mar 25, 2024
Reiterated: Buy
Price Target: $25
Current: $4.91
Upside: n/a
Jun 16, 2023
Rated: Hold
Price Target: n/a
Current: $1.33
Upside: n/a
Mar 6, 2023
Reiterated: Buy
Price Target: $21
Current: $10.54
Upside: n/a
Nov 3, 2022
Reiterated: Buy
Price Target: $23
Current: $65.68
Upside: n/a
Aug 4, 2022
Reiterated: Buy
Price Target: $25
Current: $23.30
Upside: n/a
Jul 2, 2019
Reiterated: Buy
Price Target: $7.1
Current: $9.28
Upside: n/a